Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 16Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Brain Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Gallbladder Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Solid Tumors 1Solid Tumor 1Sarcoma, Clear Cell 1Neoplasms, Unknown Primary 1Microsatellite Unstable Colorectal Cancer 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Inflammatory Breast Neoplasms 1Histiocytosis, Sinus 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Histiocytic Disorders, Malignant 1Hematologic Neoplasms 1

Interventions

trametinib 6dabrafenib 6pembrolizumab 5lenvatinib 5Paclitaxel 5Sorafenib 4Radiotherapy, Intensity-Modulated 3Doxorubicin 3pazopanib 2atezolizumab 2aldesleukin 2Taxes 2Radiotherapy 2Nivolumab 2Everolimus 2Bevacizumab 2zimberelimab 1selpercatinib 1sargramostim 1sacituzumab govitecan 1fosbretabulin 1fludarabine 1efatutazone 1cobimetinib 1ceritinib 1cemiplimab 1cabozantinib 1abemaciclib 1Vemurafenib 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Carcinoma, Anaplastic × cobimetinib × Clear all
NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡